In a retrospective combined analysis of 94 patients from three clinical trials with various mTOR inhibitors for the treatment of endometrial cancer, self-reported metformin use was associated with a higher response rate to an mTOR inhibitor (18 vs. 7%) and a lower rate of disease progression (12 vs. 33%) [15]. This evidence concerns the gene MTOR and endometrial cancer.